Country: Կիպրոս
language: հունարեն
source: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
FINASTERIDE
DELORBIS PHARMACEUTICALS LTD (0000009620) 17 ATHINON STREET, ERGATES INDUSTRIAL AREA, LEFKOSIA, 2081, 28629
D11AX10
FINASTERIDE
1MG
FILM COATED TABLETS
FINASTERIDE (8000001325) 1MG
ORAL USE
Εθνική Διαδικασία
FINASTERIDE
Νομικό καθεστώς: Με Ιατρική Συνταγή που Επαναλαμβάνεται; PACK WITH 28 TABS IN BLISTER(S) (300026504) 28 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή που Επαναλαμβάνεται
GROWFIN 1 MG FILM-COATED TABLETS. Finasteride 1 mg film-coated tablets. This medicine is for use in men only IN THIS LEAFLET: 1. What Growfin is and what it is used for 2. Before you take Growfin 3. How to take Growfin 4. Possible side effects 5. How to store Growfin 6. Further information 1. What T is and what Growfin contains a medicine called finasteride. This belongs to a group of medicines called Type II ‘5-alpha reductase inhibitors’. Your doctor has prescribed Growfin because you have male pattern hair loss (also known as androgenetic alopecia). Growfin increases hair growth on the scalp and prevents further hair loss in men. Men with mild to moderate, but not complete hair loss, can benefit from using Growfin. HOW DOES THE HAIR ON YOUR HEAD GROW? On average your hair grows about 1 centimetre (half an inch) each month. Hair grows from hair follicles, which are located under your skin. A single scalp hair grows continuously for 2-4 years (growth phase) and then stops growing for 2-4 months (rest phase). After this the hair falls out. In its place a new healthy hair begins to grow, and the cycle is repeated. The hairs on your scalp are always in different stages of this cycle so it is normal to lose scalp hair every day. WHAT IS MALE PATTERN HAIR LOSS? Male pattern hair loss is a common condition in which men experience thinning of the hair on the scalp, often resulting in a receding hairline and/or balding on the top of the head. This condition is thought to be caused by a combination of genetic factors and a particular hormone, DHT (dihydrotestosterone). 1 PATIENT INFORMATION LEAFLET READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE: Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects get serious, or if you notice any side effects not listed read_full_document
1. NAME OF THE MEDICINAL PRODUCT Growfin 1 mg Finasteride 1 mg Film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet of 'Growfin' contains 1 mg of Finasteride as the active ingredient. Excipient(s) with known effect: 95.55 mg of lactose monohydrate per film-coated tablet. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Round biconvex, reddish brown, 7 mm, marked “F1” on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ‘Growfin' is indicated for the treatment of men with male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss. 'Growfin' is NOT indicated for use in women or children and adolescents. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The recommended dosage is one 1 mg tablet daily. 'Growfin' may be taken with or without food. There is no evidence that an increase in dosage will result in increased efficacy. Efficacy and duration of treatment should continuously be assessed by the treating physician. Generally, three to six months of once daily treatment are required before evidence of stabilisation of 1 SUMMARY OF PRODUCT CHARACTERISTICS hair loss can be expected. Continuous use is recommended to sustain benefit. If treatment is stopped, the beneficial effects begin to reverse by six months and return to baseline by 9 to 12 months. No dosage adjustment is required in patients with renal insufficiency. No data are available on the concomitant use of finasteride and topical minoxidil in male pattern hair loss. 4.3 CONTRAINDICATIONS Contraindicated in women: see 4.6 'Pregnancy and lactation' and 5.1 'Pharmacodynamic properties’. Hypersensitivity to finasteride or to any of the excipients. 'Growfin' is not indicated for use in women or children and adolescents. 'Growfin' should not be taken by men who are taking finasteride 5 mg or any other 5α-reductase inhibitor for benign prostatic hyperplasia or any other condition. 4.4 SPECIAL WARNING AND PRECAUTIONS FOR USE 'Grow read_full_document